H.U. Group Holdings, Inc.

Industry

  • Services
  • Laboratory Testing Services
  • In Vitro Diagnostics

Other Names/Subsidiaries

  • Advanced Life Science Institute, Inc.
  • American Biological Technologies, Inc.
  • CanAg Diagnostics AB
  • Care'x Inc.
  • Caris Life Sciences, Inc.
  • Fornet, Inc.
  • Fujirebio Diagnostics AB
  • Fujirebio, Inc.
  • Fujirebio Diagnostics Inc.
  • Fujirebio Europe N.V.
  • GUNMA Clinical-Laboratory Information Center Inc.
  • HOKUSHIN Clinical Laboratory, Inc.
  • Innogenetics N.V..
  • Japan Clinical Laboratories, Inc.
  • Japan Pathology Laboratory Inc.
  • Kyushu Sterile Co., Ltd.
  • Life Information Analysis Center, Inc.
  • Miraca Holdings
  • Nanshin Clinical Laboratories, Inc.
  • NIHON STERY CO., LTD.
  • Pleiad, Inc.
  • Rebio Gen, Inc.
  • SHIONOGI BIOMEDICAL LABORATORIES, INC.
  • SRL, Inc.
  • SRL Hokuriku, Inc.
  • SRL Hokkaido, Inc.
  • SRL Kansai, Inc.
  • SRL Laboratory Create, Inc.
  • SRL Nishi-Nihon, Inc.
  • SRL Shizuoka, Inc.
  • SRL Technosystem, Inc.
  • SSC, Inc.
  • TFB, Inc.
  • TSL, Inc.
  • Tsuchiya Enterprise, Inc.
See more in Biomedtracker

Latest on H.U. Group Holdings, Inc.

Medtech Insight

Japan Approves Country’s First SARS-CoV-2 Antigen Test Kit As It Aims To Ramp Up Testing Numbers

 
• By Phil Greenfield

Fujirebio Diagnostics Inc. has won Japanese regulatory approval for a rapid test kit for the virus that causes COVID-19, with sales of the kit starting today. This is the first antigen test kit for S

Medtech Insight

MTI Top 100: Leading Medtechs See Steady Organic Growth In A Market On The Cusp Of Change

 
• By Ashley Yeo

The top 100 publicly listed and reportable medical technology companies had global sales spanning from more than $30bn to some $100m in the lower reaches, according to the most recent year of fully re

Medtech Insight

Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer

 
• By Phil Greenfield

The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting,

Scrip

Asia Deal Watch: Zogenix Partners Japanese Rights To Pediatric Epilepsy Therapy To Nippon Shinyaku

 
• By Ian Haydock, Anju Ghangurde, Jung Won Shin, and Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Zogenix Licenses Lead Candid